News | June 12, 2022
Cantourage and Clever leaves intensify partnership for distribution of medical cannabis in Germany
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
